Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, France.
Université Paris-Saclay, Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, France; Laboratory of Radiation Oncology, Department of Radiation Oncology, Department of Oncology, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Int Rev Cell Mol Biol. 2023;378:1-30. doi: 10.1016/bs.ircmb.2023.03.002. Epub 2023 Apr 3.
Radiation-induced lymphopenia (RIL) is characterized by a significant decrease in the absolute number of lymphocytes circulating in the blood after radiotherapy. With the major shift in cancer management initiated by cancer immunotherapy (IT), the reduction of incidence of RIL appears today as an extremely promising way of potentiating the synergy between radiotherapy and immunotherapy. However, the causes of RIL and mechanisms involved are still poorly understood. Improving our knowledge on RIL is therefore essential to limit it and thus improve the quality of care delivered to patients. The objective of this review is to provide a global view of RIL from a clinical point of view, with particular emphasis on recent knowledge and avenues explored to explain RIL and especially its depletion and remission kinetics. An opening on treatment concepts to be rethought is conducted in the context of combined RT/IT treatments.
放射诱导性淋巴细胞减少症（RIL）的特征是在放射治疗后，血液中循环淋巴细胞的绝对值显著下降。随着癌症免疫治疗（IT）引发的癌症治疗方式的重大转变，降低 RIL 的发生率如今似乎是增强放疗和免疫治疗协同作用的极具前景的方法。然而，RIL 的原因和涉及的机制仍知之甚少。因此，提高我们对 RIL 的认识对于限制它从而提高患者护理质量至关重要。本综述的目的是从临床角度提供对 RIL 的全面了解，特别强调最近的知识和探索的途径，以解释 RIL，特别是其耗竭和缓解动力学。在联合 RT/IT 治疗的背景下，对需要重新思考的治疗概念进行了探讨。
